Market Cap (In USD)
7.2 Million
Revenue (In USD)
34.07 Million
Net Income (In USD)
-20.13 Million
Avg. Volume
133.44 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.61-3.9
- PE
- -0.23
- EPS
- -3.5
- Beta Value
- 0.509
- ISIN
- US09077D2099
- CUSIP
- 09077D100
- CIK
- 1858685
- Shares
- 8873932.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Dr. Hermann Luebbert Ph.D.
- Employee Count
- -
- Website
- https://www.biofrontera.us.com
- Ipo Date
- 2021-10-29
- Details
- Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
More Stocks
-
0I47
-
7707CMSC
7707
-
8518
-
KIKOYKikkoman Corporation
KIKOY
-
ESVNFE79 Resources Corp.
ESVNF
-
GGNPFPT Gudang Garam Tbk
GGNPF
-
002578
-
CSCMY